Overview
Adecatumumab (MT201)
Blinatumomab (MT103)
MT110
MT203
MT293 (TRC093)
Preclinical Candidates
 
About UsPipelineTechnologyPartneringInvestor RelationsCareers
 
   
 
Clinical and Preclinical Pipeline Overview
Product Development Stage Indication Antibody Format Target Marketing Rights
Blinatumomab (MT103) Phase 2 Acute Lymphoblastic Leukemia BiTE® CD19 Micromet
Blinatumomab (MT103) Phase 1 Non-Hodgkin´s Lymphoma BiTE CD19 Micromet
Adecatumumab (MT201) Phase 2 Colorectal Cancer IgG1 EpCAM Merck Serono
Adecatumumab (MT201)
in combination with docetaxel		 Phase 1 Metastatic Breast Cancer IgG1 EpCAM Merck Serono
MT293 (TRC093) Phase 1 Solid Tumors IgG1 Denatured Collagen TRACON Pharmaceuticals
MT110 Phase 1 Solid Tumors BiTE EpCAM Micromet
MT203 Phase 1 Inflammation IgG1 GM-CSF Nycomed
MT111 Preclinical Solid Tumors   CEA Micromet (EU)
MedImmune#1 (ROW)
BiTE antibody Preclinical Solid Tumors BiTE not disclosed Bayer Schering
BiTE N.N. Research Solid Tumors BiTE not disclosed sanofi-aventis
MT228 (MORAb-028) Preclinical Metastatic Melanoma IgM Ganglioside Morphotek#2
MT204 Preclinical Inflammation IgG1 IL-2 Micromet
#1 MedImmune is a wholly owned subsidiary of AstraZeneca PLC
#2 Morphotek, Inc. is a wholly owned subsidiary of Eisai Co.
Back
 
   
ContactDirectionsEmail Alert 
HomeImprintLegal Notices